The hep C pipeline shrivels as Merck dumps two next-gen combos, boosting leader Gilead
Analysts are anticipating that Merck will soon have a new write-down to add to the $3 billion fine the pharma giant recorded earlier this year …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
